Currently Viewing:
Supplements Implications of Early Treatment for Parkinson’s Disease [CME/CPE]

Participating Faculty

Implications of Early Treatment for Parkinson's Disease

 

This supplement to The American Journal of Managed Care reviews the primary rationales for early diagnosis and treatment of Parkinson's disease as well as the importance of treating Parkinson's disease-related comorbidities to improve quality of life and delay functional impairment.





The contents of this supplement may include information regarding the use of products that may be inconsistent with or outside the approved labeling for these products in the United States. Physicians and pharmacists should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.









Faculty





Jack J. Chen, PharmD

Associate Professor of Neurology

Loma Linda University

Loma Linda, California





Robert A. Hauser, MD, MBA

Professor of Neurology, Molecular Pharmacology and Physiology

Director, Parkinson's Disease and Movement Disorders Center

University of South Florida

Tampa, Florida





Kelly E. Lyons, PhD

Research Associate Professor of Neurology

University of Kansas

Medical Center

Director of Research and Education

Parkinson's Disease and Movement Disorder Center

Kansas City, Kansas





Rajesh Pahwa, MD

Laverne and Joyce Rider

Professor of Neurology

Director, Parkinson's Disease and Movement Disorder Center

University of Kansas Medical Center

Kansas City, Kansas





Faculty Disclosures





These faculty have disclosed the following relevant commercial financial relationsips or affiliations in the past 12 months.





Jack J. Chen, PharmD

Honoraria/lecturer:

Teva





Robert A. Hauser, MD, MBA

Honoraria/lecturer:

Allergan Neuroscience, Biogen Idec, Boehringer Ingelheim, Embryon, GE Healthcare, Genzyme, GlaxoSmithKline, Impax, Ipsen Pharmaceuticals, Kyowa Pharmaceutical, Merck Serono International, Novartis, Quintiles, Santhera, Schering Plough, Solvay, Synosia Therapeutics, Teva Neuroscience, UCB, Xenoport





Kelly E. Lyons, PhD

Consultant/advisory board/honoraria:

Teva





Rajesh Pahwa, MD

Consultant/advisory board/honoraria:

Teva





The planning staff from the University of Cincinnati, The American Journal of Managed Care, and the Pharmacy Times Office of Continuing Professional Education have no relevant financial relationships to disclose.





Implications of Early Treatment for Parkinson's Disease

 

Release date: March 15, 2010

Expiration date: March 31, 2011

Estimated time to complete activity: 2.5 hours

 

This activity is supported by an educational grant from Teva Neurosciences, Inc.

 

Intended Audience

The audience for this supplement consists of medical directors, pharmacy directors, pharmacy and therapeutic committee members, and healthcare providers who oversee the care of patients with Parkinson's disease.

 

Statement of Educational Need/Program Overview

This educational activity will address knowledge and practice gaps that may prevent clinicians from achieving the best possible outcomes in the care of patients with Parkinson's disease (PD).

 

PD is a chronic neurodegenerative disease for which current standard treatment is generally limited to symptomatic therapies. Unfortunately, the most common symptomatic therapy, levodopa, is associated with significant side effects; therefore, its use is typically delayed until functional impairment emerges in the PD patient. Because of this delay, there are additional burdens set upon both the patient and the healthcare system.

 

There are existing and emerging treatments and strategies that have the potential to improve outcomes and delay disease progression. It is the goal of this program to provide practitioners with knowledge of the overall impact of PD and early treatment, methods for identification and diagnosis of patients with PD, and evidence-based strategies for early treatment of PD.

 

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be able to:

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up